Resource > Articles >
Harnessing Microphysiological Systems to Bring Humanized Processes to ADME and Bioavailability Studies
This article is taken from American Pharmaceutical Review, December 2023
Filed under: ADME and Drug bioavailability
Dr. Abbas discusses the common drawbacks of using conventional methods for ADME studies that can misinform the candidate selection process and dosage figures. He talks about how emerging complementary technologies, such as organ-on-a-chip (OOC), offer human-relevant in vitro preclinical data, and how using OOC can support the determination of human bioavailability to support drug dosing regiments, reduce side effects, and potentially recover flawed therapeutic candidates.